SEC Charges Zymergen Inc. With Misleading IPO Investors About Company’s Market Potential and Sales Prospects

The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline…

Read the Full Press Release

---

Have a securities law question? Call New York Securities Lawyers at 212-509-6544.